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Author’s reply
Sirs, Dr Brinker and Dr Avigan from the FDA com-
mented on four aspects of our systematic review of
ischaemic colitis (IC) in order to conclude that IC is not
increased in patients with irritable bowel syndrome
(IBS).1 This topic has only recently begun to be explored
and observational database studies have potential
limitations, so we welcome their comments.
Impact of age on incidence. We agree with the authors
that age is an extremely important risk factor for IC and
we stressed this in our article.
Misclassification of intestinal ischaemia as ischaemic coli-
tis. Brinker and Avigan suggest that because a single
diagnostic code may be used for all forms of intestinal
ischaemia, inclusion of other cases of vascular insuffi-
ciency resulted in an overestimate of the incidence of IC.
However, this is an incorrect assessment of the studies we
included because these studies did not rely solely upon a
single non-specific diagnostic code. One study required
confirmation with clearly defined endoscopic, radiologi-
cal and histological findings of IC. For two other studies,
records of patients with the vascular insufficiency
diagnostic code (557) had been prospectively assessed
to develop an algorithm that would identify IC with high
specificity and this algorithmwas validated and thenused
to identify IC cases;2 this is the same data source the FDA
authors used for their abstract.3 The fourth study, from
the UK, used codes specific for IC. This UK studymay have
given an underestimate of cases because most of the
diagnoses were made at death, suggesting only the most
severe caseswere identified. Furthermore, IC accounts for
most cases of mesenteric ischaemia.
Referral to specialists increases the ascertainment of IC. We
agree that referral to a gastroenterologist may increase
the chance of diagnosing IC or it may be that those with
symptoms of IC are more likely to be referred. However,
it seems that <10% of people with IBS see a specialist.4, 5
IC is misdiagnosed as IBS. The authors quote their recent
abstract indicating a much higher IC incidence when IC
is diagnosed within 3 weeks of the first IBS claim.3
Nevertheless, their data still show a rate of 53 per
100 000 person-years when the diagnosis of IC is made
more than 1 year after the first IBS claim – compared
with a rate of 7.2 per 100 000 person-years in the
general population of the database they studied.2 When
adjusted for confounding factors such as age, gender
and calendar year, the relative risk of IC among patients
with an IBS diagnosis for at least 1 year was 3.1 (95%
CI 2.1–4.5).2 Thus, although there may be initial
misclassification of IC as IBS, data from Brinker et al.3
clearly show a higher rate of IC in patients with
established IBS than in the general population.
Finally, a very recent abstract, representing the largest
study carried out on this topic, reported an age and
gender-adjusted significant relative risk of 3.2 (95% CI
2.5–3.9) for the development of IC among IBS patients,6
providing further support for the association.
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